Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

European stocks were higher on Friday, as markets in the region reopened following a closure for the Christmas holiday.

Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental ...

The latest health news includes WuXi's sale of its Advanced Therapies unit due to US restrictions, expanding famine in Sudan ...

Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...

Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

Elon Musk, 53, shared on Wednesday that he uses Mounjaro, a weight-loss medication, after previously endorsing similar drugs ...